Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Registration

Registration

NCT05119179

Study type

INTERVENTIONAL

Phase

PHASE4

Masking

NONE

Status

RECRUITING

Enrollment

300

Start

2021-11-22

Primary completion

2026-10-31

Lead sponsor

The University of Texas Health Science Center, Houston

Conditions

PreDiabetes

Interventions

DRUG:Semaglutide

Results posted

FALSE

Individual participant data sharing

NO

Secondary identifiers

NIH:5R01DK127084

Registered primary outcomes

• Mean change in beta cell responsivity [12 weeks]
• Insulin Sensitivity [12 weeks]
• Disposition Index [12 weeks]
• GLP-1-Induced Potentiation [12 weeks]
• Mean change in GLP-1 Area Under the Curve (AUC) [12 weeks]
• Gene expression changes for minor variants of eQTLs for TCF7L2 [12 weeks]
• Gene expression changes for minor variants of eQTLs for KCNQ1 [12 weeks]
• Gene expression changes for minor variants of eQTLs for WFS1 [12 weeks]
• Gene expression changes for minor variants of eQTLs for THADA [12 weeks]
• Gene expression changes for minor variants of eQTLs for CNR1 [12 weeks]
• Gene expression changes for minor variants of eQTLs for CTRB1 [12 weeks]
• Gene expression changes for minor variants of eQTLs for CTRB2 [12 weeks]
• Gene expression changes for minor variants of eQTLs for GLP1R [12 weeks]
• Gene expression changes for minor variants of eQTLs for CHST3 [12 weeks]
• Gene expression changes for minor variants of eQTLs for MTNR1B [12 weeks]
• Gene expression changes for minor variants of eQTLs for SORCS1 [12 weeks]
• Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge [12 weeks]